Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PD173074
i
Other names:
PD173074, PD 0173074, PD-0173074, PD0173074, SYN-1176
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(10)
News
Trials
Company:
Pfizer
Drug class:
Tyrosine kinase inhibitor
Related drugs:
‹
BBT-176 (5)
E 3810 (4)
befotertinib (3)
CLN-081 (2)
AG-1296 (1)
vorolanib (1)
KC1036 (1)
rilertinib (1)
quercetin (0)
Tyrosine Kinase inhibitors (0)
SU5416 (0)
XL092 (0)
BBT-176 (5)
E 3810 (4)
befotertinib (3)
CLN-081 (2)
AG-1296 (1)
vorolanib (1)
KC1036 (1)
rilertinib (1)
quercetin (0)
Tyrosine Kinase inhibitors (0)
SU5416 (0)
XL092 (0)
›
Associations
(10)
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
infigratinib + PD173074
Sensitive: C3 – Early Trials
infigratinib + PD173074
Sensitive
:
C3
infigratinib + PD173074
Sensitive: C3 – Early Trials
infigratinib + PD173074
Sensitive
:
C3
FGFR2-AHCYL1 fusion
Cholangiocarcinoma
FGFR2-AHCYL1 fusion
Cholangiocarcinoma
infigratinib + PD173074
Sensitive: C3 – Early Trials
infigratinib + PD173074
Sensitive
:
C3
infigratinib + PD173074
Sensitive: C3 – Early Trials
infigratinib + PD173074
Sensitive
:
C3
FGFR2 mutation
Endometrial Cancer
FGFR2 mutation
Endometrial Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
FGFR3 V555M
Multiple Myeloma
FGFR3 V555M
Multiple Myeloma
PD173074
Resistant: D – Preclinical
PD173074
Resistant
:
D
PD173074
Resistant: D – Preclinical
PD173074
Resistant
:
D
FGFR2 N550K
Endometrial Cancer
FGFR2 N550K
Endometrial Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
FGFR3 S249C
Urothelial Cancer
FGFR3 S249C
Urothelial Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
FGFR1 amplification
Breast Cancer
FGFR1 amplification
Breast Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
NRAS G13N
Multiple Myeloma
NRAS G13N
Multiple Myeloma
PD173074
Resistant: D – Preclinical
PD173074
Resistant
:
D
PD173074
Resistant: D – Preclinical
PD173074
Resistant
:
D
FGFR1 overexpression
Bladder Cancer
FGFR1 overexpression
Bladder Cancer
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
FGFR expression
Cholangiocarcinoma
FGFR expression
Cholangiocarcinoma
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
PD173074
Sensitive: D – Preclinical
PD173074
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login